MElanoma Research Lymph Node Prediction Implementation National_001 (MERLIN_001)
1. The predictive capability of CP-GEP to identify primary cutaneous melanoma patients who can safely forgo sentinel lymph node biopsy 2. The prognostic value of CP-GEP regarding the outcome of cutaneous melanoma patients after a negative sentinel lymph node biopsy.
- Newly diagnosed (biopsy within 120 days of study enrollment) invasive malignant melanoma of the skin; pT1b-pT3 (Breslow thickness ≥0.8 mm to 4.0 mm) cN0M0 OR pT1a (Breslow thickness > Male or female, age ≥18 years.
- Elected to undergo sentinel lymph node biopsy per the treating physician’s recommendation.
- Full primary melanoma pathology report unavailable.
- Documented clinically apparent nodal metastases at diagnosis.
- Distant metastatic disease (M1a,b,c,d) clinically present at primary diagnosis
- Any prior or concurrent primary invasive melanoma mapping to the same draining lymph node basin(s).
- Documented history of another (prior or concurrent) primary invasive melanoma of T1b or greater at any site within the last 5 years.
- Previous surgery in or radiation therapy to the draining lymph node basin(s) of the current primary melanoma.
- Ocular, vulvar, perianal or mucosal melanomas or melanocytic tumors of uncertain malignant potential (MELTUMP) or atypical Spitz tumors.
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.